HERLEV, Denmark, Feb. 6, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, today announced that the company's extracellular matrix (ECM) biomarker, PRO-C3 (nordicPRO-C3™) will be available as a research use only (RUO) product in China at LabCorp. All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark.

丹麦赫列夫，2024年2月6日/PRNewswire/--领先的生物标志物公司北欧生物科学公司今天宣布，该公司的细胞外基质（ECM）生物标志物PRO-C3（nordicPRO-C3™)将作为研究用途（RUO）产品在中国LabCorp上市。中国以外的所有测试仍然只在丹麦赫列夫的北欧生物科学实验室提供。

The availability of PRO-C3 as RUO in China will allow drug developers and scientists in China pre-IVD access to PRO-C3, which will be offered via LabCorp in Shanghai..

PRO-C3 as RUO在中国的可用性将允许中国的药物开发人员和科学家在IVD前获得PRO-C3，PRO-C3将通过上海的LabCorp提供。。

Continue Reading

继续阅读

PRO-C3 (nordicPRO-C3™) biomarker for chronic diseases with a fibrotic component to become available in China in a licence agreement between Nordic Bioscience and Roche, at LabCorp, Shanghai

PRO-C3（nordicPRO-C3™) 北欧生物科学公司（Nordic Bioscience）与罗氏公司（Roche）在上海LabCorp签订的许可协议中，将在中国提供具有纤维化成分的慢性病生物标志物

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH, also known as MASH), idiopathic pulmonary fibrosis (IPF) and multiple cancer types with solid tumors.

PRO-C3生物标志物与具有纤维化成分的特别慢性疾病的药物开发相关，例如非酒精性脂肪性肝炎（NASH，也称为MASH），特发性肺纤维化（IPF）和具有实体瘤的多种癌症类型。

'This collaboration will allow faster and broader access to Nordic's precision medicine enabling biomarker PRO-C3. We are very happy to be able to help drug developers in their efforts to bring new drugs for debilitating and deadly chronic diseases to market faster, more cost-efficiently, and in the future, have the potential to improve patients' lives' said Morten A.

“这种合作将使人们能够更快、更广泛地获得北欧精准医学的生物标志物PRO-C3。Morten A.说：“我们很高兴能够帮助药物开发人员努力将治疗衰弱和致命慢性病的新药更快、更具成本效益地推向市场，并且在未来有可能改善患者的生活。”。

Karsdal, Chief Executive Officer of Nordic Bioscience..

北欧生物科学首席执行官Karsdal。。

The PRO-C3 biomarker quantifies the formation of type lll collagen via measurements in blood samples. Moreover, the FDA has recently issued a Letter of Support for further investigations of the PRO-C3 biomarker as a proposed prognostic biomarker in clinical trials of patients with solid tumors. Tumor fibrosis is a common denominator in a proportion of patients across solid tumor types and is associated with a more aggressive tumor progression and poor overall survival.The PRO-C3 biomarker assay is measured on the fully automated cobas® e platform from Roche.

PRO-C3生物标志物通过血液样本中的测量来量化lll型胶原蛋白的形成。此外，FDA最近发布了一封支持函，支持进一步研究PRO-C3生物标志物作为实体瘤患者临床试验中拟议的预后生物标志物。肿瘤纤维化是实体瘤类型中一部分患者的共同特征，并且与更具侵袭性的肿瘤进展和较差的总体存活率相关。PRO-C3生物标志物测定在罗氏的全自动cobas®e平台上进行测量。

Until now it has only been possible to measure PRO-C3 in the Nordic Bioscience laboratory in Herlev, Denmark, but RUO availability in China facilitates broader market access.The license agreement between Nordic Bioscience and Roche will put multiple Nordic Bioscience biomarkers on the fully automated cobas® e platform from Roche over the coming years.

到目前为止，只有在丹麦赫列夫的北欧生物科学实验室才能测量PRO-C3，但RUO在中国的可用性有助于更广泛的市场准入。北欧生物科学公司（Nordic Bioscience）与罗氏公司（Roche）之间的许可协议将在未来几年将多个北欧生物科学生物标志物置于罗氏公司（Roche）的全自动cobas®e平台上。

This enables better research and drug development in chronic disease in which the ECM and collagens are central components. That is the case for almost 50 chronic diseases that until now have limited treatment options and represent a major challenge for patients and society.For more information please contact:Nordic Bioscience A/SHerlev Hovedgade 205-2072730 Herlev, Denmarkpreferably via email [email protected] Tel.

这使得能够更好地研究和药物开发以ECM和胶原蛋白为核心成分的慢性疾病。这是近50种慢性病的情况，到目前为止，这些慢性病的治疗选择有限，对患者和社会构成了重大挑战。有关更多信息，请联系：Nordic Bioscience A/SHerlev Hovedgedade 205-2072730 Herlev，Denmark，最好通过电子邮件[电子邮件保护]电话联系。

+45 4452 5252For product related inquires please use https://www.nordicbioscience.com/contact About Nordic BioscienceNordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research.

+45 4452 5252有关产品的查询，请使用https://www.nordicbioscience.com/contact关于北欧生物科学Nordic Bioscience是一家丹麦生物标志物公司，总部位于丹麦赫列夫。北欧生物科学公司使用我们独特的新表位技术从事生物标志物开发。我们将生物标志物开发方面的专业知识与临床前和临床研究相结合。

This enables us to develop biomarkers that provide fast and objective decision.

这使我们能够开发提供快速和客观决策的生物标志物。